| Year |
Citation |
Score |
| 2023 |
Liang H, Wang X, Peng Y, Niu Y. Improving marginal hazard ratio estimation using quadratic inference functions. Lifetime Data Analysis. PMID 37149514 DOI: 10.1007/s10985-023-09598-4 |
0.522 |
|
| 2020 |
Yang L, Song H, Peng Y, Tu D. Joint analysis of longitudinal measurements and survival times with a cure fraction based on partly linear mixed and semiparametric cure models. Pharmaceutical Statistics. PMID 33225606 DOI: 10.1002/pst.2082 |
0.497 |
|
| 2020 |
Ge X, Peng Y, Tu D. A threshold linear mixed model for identification of treatment-sensitive subsets in a clinical trial based on longitudinal outcomes and a continuous covariate. Statistical Methods in Medical Research. 962280220912772. PMID 32193992 DOI: 10.1177/0962280220912772 |
0.688 |
|
| 2020 |
Jamaspishvili T, Patel PG, Niu Y, Vidotto T, Caven I, Livergant R, Fu W, Kawashima A, How N, Okello JB, Guedes LB, Ouellet V, Picanço C, Koti M, Reis RB, ... ... Peng YP, et al. Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN). Journal of the National Cancer Institute. PMID 32129857 DOI: 10.1093/Jnci/Djaa032 |
0.461 |
|
| 2020 |
Niu Y, Wang X, Cao H, Peng Y. Variable selection via penalized generalized estimating equations for a marginal survival model. Statistical Methods in Medical Research. 962280220901728. PMID 31994449 DOI: 10.1177/0962280220901728 |
0.588 |
|
| 2020 |
Saleh R, Bedard PL, Nguyen P, Malone ER, Yu C, Amir E, Earle C, Gyawali B, Hansen AR, Mittmann N, Peng Y, Pugh TJ, Abdul Razak AR, Sabatini P, Spreafico A, et al. An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors. Journal of Clinical Oncology. 38: e19303-e19303. DOI: 10.1200/Jco.2020.38.15_Suppl.E19303 |
0.344 |
|
| 2020 |
Raphael MJ, Siemens R, Peng Y, Vera-Badillo FE, Booth CM. Volume of systemic cancer therapy delivery and outcomes of patients with solid tumors: A systematic review and methodologic evaluation of the literature Journal of Cancer Policy. 23: 100215. DOI: 10.1016/J.Jcpo.2020.100215 |
0.315 |
|
| 2019 |
Karim S, Mackillop WJ, Brennan K, Peng Y, Siemens DR, Krzyzanowska MK, Booth CM. Estimating the optimal perioperative chemotherapy utilization rate for muscle-invasive bladder cancer. Cancer Medicine. PMID 31472011 DOI: 10.1002/Cam4.2449 |
0.307 |
|
| 2019 |
Karim S, Booth CM, Brennan K, Peng Y, Siemens DR, Krzyzanowska MK, Mackillop WJ. Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer. Cancer Medicine. PMID 31407518 DOI: 10.1002/Cam4.2456 |
0.324 |
|
| 2019 |
Merchant SJ, Brogly SB, Booth CM, Goldie C, Peng Y, Nanji S, Patel SV, Lajkosz K, Baxter NN. Management of Cancer-Associated Intestinal Obstruction in the Final Year of Life. Journal of Palliative Care. 825859719861935. PMID 31307272 DOI: 10.1177/0825859719861935 |
0.303 |
|
| 2019 |
Jamaspishvili T, Patel P, Niu Y, Vidotto T, Caven I, Livergant R, Fu W, Ouellet V, Picanço C, Koti M, How N, Saad F, Mes-Masson AM, Lotan T, Squire J, ... Peng Y, et al. MP28-02 QUANTITATIVE MEASUREMENT OF PTEN LOSS IMPROVES RISK ASSESSMENT IN PROSTATE CANCER. The Journal of Urology. 201: e403. PMID 30950708 DOI: 10.1097/01.Ju.0000555707.15264.F6 |
0.502 |
|
| 2019 |
Drysdale E, Peng Y, Nguyen P, Baetz T, Hanna TP. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma. Melanoma Research. PMID 30789386 DOI: 10.1097/Cmr.0000000000000582 |
0.362 |
|
| 2019 |
Brennan KE, Hall SF, Yoo J, Rohland SL, Theurer J, Peng Y, Feldman-Stewart D. Routine follow-up care after curative treatment of head and neck cancer: A survey of patients' needs and preferences for healthcare services. European Journal of Cancer Care. e12993. PMID 30656777 DOI: 10.1111/Ecc.12993 |
0.319 |
|
| 2018 |
Hanna TP, Chauvin C, Miao Q, Rizkalla M, Reid K, Peng Y, Nguyen P, Jalink D, Nanji S. Clinical Outcomes Following Pulmonary Metastasectomy for Melanoma: A Population-Based Study. The Annals of Thoracic Surgery. PMID 30171851 DOI: 10.1016/J.Athoracsur.2018.06.078 |
0.312 |
|
| 2018 |
Niu Y, Wang X, Peng Y. geecure: An R-package for marginal proportional hazards mixture cure models. Computer Methods and Programs in Biomedicine. 161: 115-124. PMID 29852954 DOI: 10.1016/J.Cmpb.2018.04.017 |
0.548 |
|
| 2018 |
Niu Y, Song L, Liu Y, Peng Y. Modeling clustered long-term survivors using marginal mixture cure model. Biometrical Journal. Biometrische Zeitschrift. PMID 29733452 DOI: 10.1002/Bimj.201700114 |
0.587 |
|
| 2018 |
Brennan KE, Hall SF, Owen TE, Griffiths RJ, Peng Y. Variation in routine follow-up care after curative treatment for head-and-neck cancer: a population-based study in Ontario. Current Oncology (Toronto, Ont.). 25: e120-e131. PMID 29719436 DOI: 10.3747/Co.25.3892 |
0.328 |
|
| 2017 |
Booth CM, Karim S, Brennan K, Siemens DR, Peng Y, Mackillop WJ. Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing? Urologic Oncology. PMID 29254673 DOI: 10.1016/J.Urolonc.2017.11.015 |
0.331 |
|
| 2017 |
Booth CM, Karim S, Peng Y, Siemens DR, Brennan K, Mackillop WJ. Radical Treatment of the Primary Tumor in Metastatic Bladder Cancer: Potentially Dangerous Findings From Observational Data. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017761759. PMID 29236572 DOI: 10.1200/Jco.2017.76.1759 |
0.308 |
|
| 2017 |
Karim S, Brennan K, Peng Y, Mackillop WJ, Booth CM. Estimating the optimal rate of adjuvant chemotherapy utilization in stage III colon cancer. Journal of Clinical Oncology. 35: 6591-6591. DOI: 10.1200/Jco.2017.35.15_Suppl.6591 |
0.313 |
|
| 2016 |
Booth CM, Nanji S, Wei X, Peng Y, Biagi JJ, Hanna TP, Krzyzanowska MK, Mackillop WJ. Adjuvant Chemotherapy for Stage II Colon Cancer: Practice Patterns and Effectiveness in the General Population. Clinical Oncology (Royal College of Radiologists (Great Britain)). PMID 27663601 DOI: 10.1200/Jco.2016.34.15_Suppl.6569 |
0.326 |
|
| 2016 |
Peng Y, Taylor JM. Residual-based model diagnosis methods for mixture cure models. Biometrics. PMID 27598783 DOI: 10.1111/Biom.12582 |
0.366 |
|
| 2016 |
Sun J, Niu Y, Wang C, Zhang H, Xie B, Xu F, Jin H, Peng Y, Liang L, Xu P. Discovery of 3-benzyl-1,3-benzoxazine-2,4-dione analogues as allosteric mitogen-activated kinase kinase (MEK) inhibitors and anti-enterovirus 71 (EV71) agents. Bioorganic & Medicinal Chemistry. PMID 27288186 DOI: 10.1016/J.Bmc.2016.05.055 |
0.389 |
|
| 2016 |
Chandhoke G, Wei X, Nanji S, Biagi J, Peng Y, Krzyzanowska M, Mackillop WJ, Booth CM. Patterns of Referral for Adjuvant Chemotherapy for Stage II and III Colon Cancer: A Population-Based Study. Annals of Surgical Oncology. PMID 26965700 DOI: 10.1245/S10434-016-5181-8 |
0.36 |
|
| 2016 |
Robinson AG, Wei X, Mackillop WJ, Peng Y, Booth CM. Use of Palliative Chemotherapy for Advanced Bladder Cancer: Patterns of Care in Routine Clinical Practice. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 291-8. PMID 26957615 DOI: 10.6004/Jnccn.2016.0034 |
0.373 |
|
| 2016 |
Booth CM, Nanji S, Wei X, Peng Y, Biagi JJ, Hanna TP, Krzyzanowska MK, Mackillop WJ. Use and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 47-56. PMID 26733554 DOI: 10.6004/Jnccn.2016.0006 |
0.392 |
|
| 2016 |
Del Paggio J, Peng Y, Wei X, Nanji S, MacDonald PH, Krishnan Nair C, Booth CM. Re-evaluating the optimal threshold for lymph node (LN) harvest in colon cancer: Insights from a population-based study. Journal of Clinical Oncology. 34: 3610-3610. DOI: 10.1200/Jco.2016.34.15_Suppl.3610 |
0.311 |
|
| 2016 |
Song H, Peng Y, Tu D. Joint modeling of longitudinal proportional measurements and survival time with a cure fraction Science China Mathematics. 59: 2427-2442. DOI: 10.1007/S11425-016-0126-3 |
0.556 |
|
| 2015 |
Song H, Peng Y, Tu D. Jointly modeling longitudinal proportional data and survival times with an application to the quality of life data in a breast cancer trial. Lifetime Data Analysis. PMID 26403909 DOI: 10.1007/S10985-015-9346-8 |
0.547 |
|
| 2015 |
Izard JP, Siemens DR, Mackillop WJ, Wei X, Leveridge MJ, Berman DM, Peng Y, Booth CM. Outcomes of squamous histology in bladder cancer: A population-based study. Urologic Oncology. PMID 26199176 DOI: 10.1016/J.Urolonc.2015.06.011 |
0.337 |
|
| 2015 |
Leveridge MJ, Siemens DR, Mackillop WJ, Peng Y, Tannock IF, Berman DM, Booth CM. Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study. Urology. 85: 791-8. PMID 25661830 DOI: 10.1016/J.Urology.2014.12.027 |
0.362 |
|
| 2015 |
Patafio F, Brooks SC, Wei X, Peng Y, Biagi J, Booth CM. Cancer mortality and published research output: Is there any relationship? Journal of Clinical Oncology. 33: 6596-6596. DOI: 10.1200/Jco.2015.33.15_Suppl.6596 |
0.326 |
|
| 2015 |
Niu Y, Peng Y. A new estimating equation approach for marginal hazard ratio estimation Computational Statistics and Data Analysis. 87: 46-56. DOI: 10.1016/J.Csda.2015.01.012 |
0.554 |
|
| 2014 |
Siemens DR, Mackillop WJ, Peng Y, Berman D, Elharram A, Rhee J, Booth CM. Processes of care and the impact of surgical volumes on cancer-specific survival: a population-based study in bladder cancer. Urology. 84: 1049-57. PMID 25443899 DOI: 10.1016/J.Urology.2014.06.070 |
0.347 |
|
| 2014 |
Booth CM, Siemens DR, Wei X, Peng Y, Berman DM, Mackillop WJ. Pathological factors associated with survival benefit from adjuvant chemotherapy (ACT): a population-based study of bladder cancer. Bju International. PMID 25168574 DOI: 10.1111/Bju.12913 |
0.329 |
|
| 2014 |
Booth CM, Siemens DR, Peng Y, Mackillop WJ. Patterns of referral for perioperative chemotherapy among patients with muscle-invasive bladder cancer: a population-based study. Urologic Oncology. 32: 1200-8. PMID 24968946 DOI: 10.1016/J.Urolonc.2014.05.012 |
0.34 |
|
| 2014 |
Booth CM, Siemens DR, Li G, Peng Y, Kong W, Berman DM, Mackillop WJ. Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study. Clinical Oncology (Royal College of Radiologists (Great Britain)). 26: 506-14. PMID 24954284 DOI: 10.1016/J.Clon.2014.05.007 |
0.338 |
|
| 2014 |
Booth CM, Siemens DR, Peng Y, Tannock IF, Mackillop WJ. Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice Annals of Oncology. 25: 1783-1788. PMID 24915872 DOI: 10.1093/Annonc/Mdu204 |
0.357 |
|
| 2014 |
Booth CM, Siemens DR, Li G, Peng Y, Tannock IF, Kong W, Berman DM, Mackillop WJ. Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer. 120: 1630-8. PMID 24733278 DOI: 10.1002/Cncr.28510 |
0.371 |
|
| 2014 |
Booth CM, Siemens DR, Peng Y, Mackillop WJ. Patterns of referral for peri-operative chemotherapy among patients with muscle-invasive bladder cancer (MIBC): A population-based study. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E15507 |
0.355 |
|
| 2014 |
Rouette J, Blazeby JM, King M, Calvert M, Peng Y, Meyer RM, Ringash J, Walker M, Brundage MD. The use of health-related quality of life outcomes in oncology practice: An international study. Journal of Clinical Oncology. 32: 6524-6524. DOI: 10.1200/Jco.2014.32.15_Suppl.6524 |
0.335 |
|
| 2014 |
Booth CM, Siemens DR, Peng Y, Tannock I, Mackillop WJ. Delivery of peri-operative chemotherapy for muscle-invasive bladder cancer (MIBC) in routine clinical practice: Does regimen and timing matter? Journal of Clinical Oncology. 32: 4537-4537. DOI: 10.1200/Jco.2014.32.15_Suppl.4537 |
0.391 |
|
| 2014 |
Leveridge M, Siemens R, Mackillop W, Peng Y, Berman D, Booth C. MP2-03 RADICAL CYSTECTOMY AND ADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER IN THE ELDERLY: A POPULATION-BASED STUDY Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.161 |
0.317 |
|
| 2014 |
Niu Y, Peng Y. Marginal regression analysis of clustered failure time data with a cure fraction Journal of Multivariate Analysis. 123: 129-142. DOI: 10.1016/j.jmva.2013.09.003 |
0.529 |
|
| 2013 |
Wang K, Hu X, Peng Y. An analytical comparison of the principal component method and the mixed effects model for association studies in the presence of cryptic relatedness and population stratification. Human Heredity. 76: 1-9. PMID 23921716 DOI: 10.1159/000353345 |
0.346 |
|
| 2013 |
Brundage M, Danielson B, Pearcey R, Bass B, Pickles T, Bahary JP, Peng Y, Wallace D, Mackillop W. A criterion-based audit of the technical quality of external beam radiotherapy for prostate cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 107: 339-45. PMID 23830469 DOI: 10.1016/J.Radonc.2013.04.023 |
0.309 |
|
| 2013 |
Wang C, Zhang H, Xu F, Niu Y, Wu Y, Wang X, Peng Y, Sun J, Liang L, Xu P. Substituted 3-benzylcoumarins as allosteric MEK1 inhibitors: design, synthesis and biological evaluation as antiviral agents. Molecules (Basel, Switzerland). 18: 6057-91. PMID 23698055 DOI: 10.3390/Molecules18056057 |
0.394 |
|
| 2013 |
Kankesan J, Shepherd FA, Peng Y, Darling G, Li G, Kong W, Mackillop WJ, Booth CM. Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based study. Current Oncology (Toronto, Ont.). 20: 30-7. PMID 23443880 DOI: 10.3747/Co.20.1178 |
0.321 |
|
| 2013 |
Zhang J, Peng Y, Li H. A New Semiparametric Estimation Method for Accelerated Hazards Mixture Cure Model. Computational Statistics & Data Analysis. 59: 95-102. PMID 23293406 DOI: 10.1016/J.Csda.2012.09.017 |
0.402 |
|
| 2013 |
Niu Y, Peng Y. A semiparametric marginal mixture cure model for clustered survival data. Statistics in Medicine. 32: 2364-73. PMID 23203908 DOI: 10.1002/Sim.5687 |
0.601 |
|
| 2013 |
Booth CM, Shepherd FA, Peng Y, Darling G, Li G, Kong W, Biagi JJ, Mackillop WJ. Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study. Cancer. 119: 1243-50. PMID 23131995 DOI: 10.1002/Cncr.27823 |
0.349 |
|
| 2012 |
Peng Y, Niu Y, Zhang L, Yang A, Jiang L, Gong S. Enhanced optical precursors by Doppler effect via active Raman gain process. Optics Letters. 37: 3333-5. PMID 23381248 |
0.398 |
|
| 2012 |
Cai C, Zou Y, Peng Y, Zhang J. smcure: an R-package for estimating semiparametric mixture cure models. Computer Methods and Programs in Biomedicine. 108: 1255-60. PMID 23017250 DOI: 10.1016/J.Cmpb.2012.08.013 |
0.367 |
|
| 2012 |
Zhang J, Peng Y. Semiparametric Estimation Methods for the Accelerated Failure Time Mixture Cure Model. Journal of the Korean Statistical Society. 41: 415-422. PMID 22773908 DOI: 10.1016/J.Jkss.2012.01.003 |
0.365 |
|
| 2012 |
Liu X, Peng Y, Tu D, Liang H. Variable selection in semiparametric cure models based on penalized likelihood, with application to breast cancer clinical trials. Statistics in Medicine. 31: 2882-91. PMID 22733695 DOI: 10.1002/Sim.5378 |
0.407 |
|
| 2012 |
Cuffe S, Booth CM, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ, Shepherd FA. Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1813-21. PMID 22529258 DOI: 10.1200/Jco.2011.39.3330 |
0.372 |
|
| 2012 |
Hanna TP, Richardson H, Peng Y, Kong W, Zhang-Salomons J, Mackillop WJ. A population-based study of factors affecting the use of radiotherapy for endometrial cancer. Clinical Oncology. 24. PMID 22405530 DOI: 10.1016/J.Clon.2012.01.007 |
0.349 |
|
| 2012 |
Booth CM, Shepherd FA, Peng Y, Darling G, Li G, Kong W, Mackillop WJ. Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 559-66. PMID 22307012 DOI: 10.1097/Jto.0B013E31823F43Af |
0.381 |
|
| 2012 |
Peng Y, Xu J. An extended cure model and model selection. Lifetime Data Analysis. 18: 215-33. PMID 22241600 DOI: 10.1007/S10985-011-9213-1 |
0.358 |
|
| 2012 |
Kankesan J, Shepherd FA, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ, Booth CM. Factors associated with referral to medical oncology (MO) and subsequent use of adjuvant chemotherapy (ACT) among patients with resected non-small cell lung cancer (NSCLC): A population-based study. Journal of Clinical Oncology. 30: 1583-1583. DOI: 10.1200/Jco.2012.30.15_Suppl.1583 |
0.307 |
|
| 2012 |
Booth C, Siemens D, Li G, Peng Y, Tannock I, Berman D, Kong W, Mackillop W. Neoadjuvant (NACT) and Adjuvant Chemotherapy (ACT) for Muscle-Invasive Bladder Cancer: A Population-Based Outcomes Study Annals of Oncology. 23: ix260. DOI: 10.1016/S0923-7534(20)33403-7 |
0.337 |
|
| 2012 |
Song H, Peng Y, Tu D. A new approach for joint modelling of longitudinal measurements and survival times with a cure fraction Canadian Journal of Statistics. 40: 207-224. DOI: 10.1002/Cjs.11127 |
0.328 |
|
| 2011 |
Booth CM, Siemens DR, Tannock I, Peng Y, Li G, Mackillop WJ. Adoption of neoadjuvant (NACT) and adjuvant chemotherapy (ACT) for bladder cancer: A population-based study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4644. PMID 28023930 DOI: 10.1200/Jco.2011.29.15_Suppl.4644 |
0.343 |
|
| 2011 |
Cuffe S, Booth CM, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ, Shepherd FA. Adoption of adjuvant chemotherapy (ACT) for non-small cell lung cancer (NSCLC) in the elderly: A population-based outcomes study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7012. PMID 28020074 DOI: 10.1200/Jco.2011.29.15_Suppl.7012 |
0.327 |
|
| 2011 |
Zhang J, Peng Y, Zhao O. A new semiparametric estimation method for accelerated hazard model. Biometrics. 67: 1352-60. PMID 21457194 DOI: 10.1111/J.1541-0420.2011.01592.X |
0.352 |
|
| 2011 |
Peng Y, Taylor JM. Mixture cure model with random effects for the analysis of a multi-center tonsil cancer study. Statistics in Medicine. 30: 211-23. PMID 21213339 DOI: 10.1002/Sim.4098 |
0.441 |
|
| 2010 |
Booth CM, Shepherd FA, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ. Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3472-8. PMID 20567022 DOI: 10.1200/Jco.2010.28.1709 |
0.377 |
|
| 2009 |
Zhang J, Peng Y. Crossing Hazard Functions in Common Survival Models. Statistics & Probability Letters. 79: 2124-2130. PMID 20613974 DOI: 10.1016/J.Spl.2009.07.002 |
0.306 |
|
| 2009 |
Zhang J, Peng Y. Accelerated hazards mixture cure model. Lifetime Data Analysis. 15: 455-67. PMID 19697127 DOI: 10.1007/S10985-009-9126-4 |
0.426 |
|
| 2009 |
Gupta S, Kong W, Peng Y, Miao Q, Mackillop WJ. Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. International Journal of Cancer. 125: 2159-65. PMID 19569190 DOI: 10.1002/Ijc.24533 |
0.347 |
|
| 2008 |
Peng Y, Zhang J. Estimation method of the semiparametric mixture cure gamma frailty model. Statistics in Medicine. 27: 5177-94. PMID 18613271 DOI: 10.1002/Sim.3358 |
0.403 |
|
| 2008 |
Peng Y, Zhang J. Identifiability of a mixture cure frailty model Statistics & Probability Letters. 78: 2604-2608. DOI: 10.1016/J.Spl.2008.07.044 |
0.322 |
|
| 2008 |
Yu B, Peng Y. Mixture cure models for multivariate survival data Computational Statistics & Data Analysis. 52: 1524-1532. DOI: 10.1016/J.Csda.2007.04.018 |
0.41 |
|
| 2007 |
Peng Y, Taylor JM, Yu B. A marginal regression model for multivariate failure time data with a surviving fraction. Lifetime Data Analysis. 13: 351-69. PMID 17641970 DOI: 10.1007/S10985-007-9042-4 |
0.408 |
|
| 2007 |
Zhang J, Peng Y. A new estimation method for the semiparametric accelerated failure time mixture cure model. Statistics in Medicine. 26: 3157-71. PMID 17094075 DOI: 10.1002/Sim.2748 |
0.386 |
|
| 2007 |
Zhang J, Peng Y. An alternative estimation method for the accelerated failure time frailty model Computational Statistics & Data Analysis. 51: 4413-4423. DOI: 10.1016/J.Csda.2006.06.017 |
0.379 |
|
| 2006 |
Balakrishnan N, Peng Y. Generalized gamma frailty model. Statistics in Medicine. 25: 2797-816. PMID 16220516 DOI: 10.1002/Sim.2375 |
0.365 |
|
| 2004 |
Goodman AC, Peng Y, Hankin JR, Kalist DE, Spurr SJ. Estimating episode lengths when some observations are probably censored. Statistics in Medicine. 23: 2071-87. PMID 15211604 DOI: 10.1002/Sim.1798 |
0.347 |
|
| 2003 |
Peng Y, Dear KBG. An Increasing Hazard Cure Model Handbook of Statistics. 23: 545-557. DOI: 10.1016/S0169-7161(03)23031-5 |
0.412 |
|
| 2003 |
Peng Y. Fitting semiparametric cure models Computational Statistics and Data Analysis. 41: 481-490. DOI: 10.1016/S0167-9473(02)00184-6 |
0.411 |
|
| 2003 |
Peng Y. Estimating baseline distribution in proportional hazards cure models Computational Statistics and Data Analysis. 42: 187-201. DOI: 10.1016/S0167-9473(02)00158-5 |
0.423 |
|
| 2002 |
Peng Y, Carriere KC. An empirical comparison of parametric and semiparametric cure models Biometrical Journal. 44: 1002-1014. DOI: 10.1002/Bimj.200290000 |
0.413 |
|
| 2001 |
Peng Y, Dear KBG, Carriere KC. Testing for the presence of cured patients: A simulation study Statistics in Medicine. 20: 1783-1796. PMID 11406841 DOI: 10.1002/Sim.781 |
0.305 |
|
| 2000 |
Peng Y, Dear KB. A nonparametric mixture model for cure rate estimation. Biometrics. 56: 237-43. PMID 10783801 DOI: 10.1111/J.0006-341X.2000.00237.X |
0.42 |
|
| 1998 |
Peng Y, Dear KB, Denham JW. A generalized F mixture model for cure rate estimation. Statistics in Medicine. 17: 813-30. PMID 9595613 DOI: 10.1002/(Sici)1097-0258(19980430)17:8<813::Aid-Sim775>3.0.Co;2-# |
0.384 |
|
| Show low-probability matches. |